Researchers engineer rare immune cells to create powerful new cancer vaccine

In a new study published in Cancer Immunology Research, scientists at the Icahn School of Medicine at Mount Sinai have developed a novel method to generate billions of rare immune cells known as conventional type I dendritic cells (cDC1s), potentially paving the way for a new class of off-the-shelf cellular cancer vaccines.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup